The Trump administration’s December 2025 executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, prompting the Department of Justice and DEA to issue an April 2026 final order that immediately reclassified FDA-approved marijuana products and state-licensed medical marijuana to Schedule III. That order also launched a new, compressed administrative hearing process for broader rescheduling of all marijuana, set to begin June 29, 2026, and conclude no later than July 15. Traders are pricing the likelihood of full rescheduling by mid-2026 or year-end around these procedural milestones, the administration’s stated priority on accelerating the timeline, and the limited window for public comments or legal challenges before a final rule could be published. Any delays in the hearing or subsequent litigation remain the primary variables that could alter the current market consensus.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$762,399 Vol.
30 giugno
2%
31 dicembre
26%
$762,399 Vol.
30 giugno
2%
31 dicembre
26%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Trump administration’s December 2025 executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, prompting the Department of Justice and DEA to issue an April 2026 final order that immediately reclassified FDA-approved marijuana products and state-licensed medical marijuana to Schedule III. That order also launched a new, compressed administrative hearing process for broader rescheduling of all marijuana, set to begin June 29, 2026, and conclude no later than July 15. Traders are pricing the likelihood of full rescheduling by mid-2026 or year-end around these procedural milestones, the administration’s stated priority on accelerating the timeline, and the limited window for public comments or legal challenges before a final rule could be published. Any delays in the hearing or subsequent litigation remain the primary variables that could alter the current market consensus.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti